Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alketa Hamzaj

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Pageof 2